Myocardial Glucose Uptake (MGU) in Patients With Chronic Kidney Disease

• Status: Completed
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study examines patients with chronic kidney disease-related anemia and measures changes in the metabolism of the heart using FDG/PET scanning, before and 6 months after their health-care provider has initiated anemia management therapy with the FDA-approved drug darbepoetin alfa (Aranesp), which is approved for chronic kidney disease-related anemia. The investigators hypothesize that the heart has abnormal metabolism with the anemia of chronic kidney disease but this improves after correction of this anemia with darbepoetin alfa.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Maryland; University of Maryland, Baltimore
• Collaborator: Amgen
• Treatments: Darbepoetin alfa

Criteria

Inclusion Criteria:

• Participant must receive care at the VAMHCS (VA Hospital) in Baltimore

• Diagnosed with CKD stage 3 to 5 (eGFR of 60 ml/min/1.73m2) and not expected to initiate renal replacement therapy within 6 months

• Anemia related CKD.

• The last 2 serum hemoglobin (Hb) values less than 11.0 gm/dl but greater than 8.0 gm/dl

• Greater than 18 years of age

• Assessed to be clinically stable by the clinician

Exclusion Criteria:

• Need for hemodialysis, peritoneal dialysis, or transplantation at the time of enrollment or projected to start within 6 months after enrollment

• Low functional capacity including inability to walk a flight of stairs with a bag of groceries (NYHA Class III/IV Heart Failure)

• Prior erythropoietic agents within last 12 weeks

• TSAT < 15% and not receiving the recommended dose for iron deficiency

• Uncontrolled hypertension defined as greater than 180 mm Hg systolic or 110 mm Hg diastolic

• Potentially "brittle" diabetes with the propensity for symptomatic hypoglycemia after a 6 hour fast

• New diagnosis or ongoing therapy for Cancer

• Pregnancy